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Abstract: Due to the rapid urbanization of the world population, a better understanding of 
the detrimental effects of exposure to urban air pollution on chronic lung disease is necessary. 
Strong epidemiological evidence suggests that exposure to particulate matter (PM) air pollution 
causes exacerbations of pre-existing lung conditions, such as, chronic obstructive pulmonary 
disease (COPD) resulting in increased morbidity and mortality. However, little is known whether 
a chronic, low-grade exposure to ambient PM can cause the development and progression of 
COPD. The deposition of PM in the respiratory tract depends predominantly on the size of the 
particles, with larger particles deposited in the upper and larger airways and smaller particles 
penetrating deep into the alveolar spaces. Ineffective clearance of this PM from the airways 
could cause particle retention in lung tissues, resulting in a chronic, low-grade inflammatory 
response that may be pathogenetically important in both the exacerbation, as well as, the pro-
gression of lung disease. This review focuses on the adverse effects of exposure to ambient PM 
air pollution on the exacerbation, progression, and development of COPD.
Keywords: chronic obstructive pulmonary disease, particulate matter, air pollution, alveolar 
macrophage
Introduction
The first, and arguably, most reported event that associated mortality with exposure to 
air pollution occurred from December 5th to the 9th 1952, in London, England. During 
the “London Fog”, over 4000 more deaths than normal occurred during that period, pre-
dominantly due to heart and lung conditions. This episode in London, along with many 
others, brought attention to the impact of air pollution on human health1 and focused 
the scientific community on studying the adverse health effects of ambient air pollution. 
Even before recorded human history 5,300 years ago, the Tyrolean Iceman, who was 
discovered in September of 1991, had dust and carbon retained in his lung tissue.2 For 
centuries, human beings have been dealing with suspended particulate matter (PM) from 
dirt and burning of biomass for the purposes of cooking and warmth.3 In present day, the 
human respiratory tract has to deal with a much wider variety of ambient particles and 
gasses, predominantly from cigarette smoke, vehicle exhaust, and industrial sources.
Subjects with chronic lung conditions are particularly susceptible to the adverse 
effects of ambient PM.3 One such condition of particular importance, chronic 
obstructive pulmonary disease (COPD), is a progressive inflammatory condition of 
the airways, pulmonary vessels, and lung parenchyma.4,5 COPD is a worldwide pub-
lic health problem with significant morbidity and mortality and has been projected 
to be the 3rd leading cause of total mortality and the 5th leading cause of disability International Journal of COPD 2009:4 234
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by 2020.6,7 Because COPD is the most prevalent chronic 
lung condition; this population is particularly susceptible 
to the adverse health effects of ambient pollutants. In this 
review, we will focus on the effects of air pollution on the 
exacerbation, progression, and development of COPD.
COPD: An important public health 
problem
Worldwide, COPD is among one of the fastest growing chronic 
diseases in both the developed and the developing world.8 The 
clinical hallmark of COPD is progressive airflow limitation 
that is not reversible.9 In population-based studies, COPD 
affects 5% to 19% of the adult population above 40 years of 
age.10 Its prevalence has risen by 41% since 1982, and its age-
adjusted mortality rate has increased by over 100% between 
1970 and 2002.11–13 The economic costs for the management 
of this disease are staggering and these costs do not take into 
account the social burden of a reduced quality of life.14,15 While 
these figures are alarming, the true health burden of COPD is 
under-estimated, because airflow obstruction also significantly 
predisposes patients to other common causes of morbidity and 
mortality, including ischemic heart disease, stroke, pneumonia, 
and lung cancer.16,17
Causes of COPD
COPD is a progressive inflammatory condition of the 
lung caused predominantly by inhalation of noxious gas-
ses and PM.4–7 Cigarette smoking (active or passive) is 
thought to be responsible for the vast majority of COPD; 
however, increasingly, other sources of exposure such 
as the burning of biomass fuels for heating and cooking, 
working in polluted indoor and outdoor environments, and 
exposure to ambient PM by exhaust from internal com-
bustion engines, industrial emissions, and forest fires, are 
recognized as significant contributors to the development, 
progression, and exacerbation of COPD.18–23 Among all 
the lung diseases, COPD is the most highly correlated with 
air pollution exposure and has been linked to rapid global 
urbanization.18–22 The second major determinant of COPD 
is the host response to these inhaled stimuli where persons 
with α-1 antitrypsin deficiency,24 a positive family history 
for COPD,25,26 a history of repeated respiratory tract infec-
tions in childhood,27 increased responsiveness to inhaled 
irritants,28 and female gender29,30 have been shown to be at 
greater risk for an equivalent exposure to chronic inhala-
tion injury. The repetitive nature of this inhalation injury 
is central to all these exposures and pivotal to the chronic 
and progressive nature of COPD.
Particulate matter exposure and COPD
Epidemiological evidence
The relationship between increased levels of air pollution and 
the mortality and morbidity rates from respiratory diseases is 
well-established.31,32 Respiratory morbidity and mortality are 
also related to admissions for pneumonia, asthma, pulmonary 
emboli, and COPD.33 Of all the pollutants, inhalable particulate 
matter (PM10) shows a strong association with adverse respira-
tory health effects, even when adjusted for other major risk fac-
tors such as cigarette smoking.31 Acute exacerbations of COPD, 
chronic bronchitis (CB), or emphysema have been associated 
with short-term exposure to air pollution.33 Older studies have 
shown that high levels of ambient particles were related to 
increased prevalence of chronic bronchitis34 and more recent 
studies predominantly relate respiratory symptoms to long-term 
effects of ambient particles.35,36 Recent cross-sectional studies 
showed an association between exposure to ambient PM10 in 
particular urban traffic related PM, a decline in forced expira-
tory volume in one second (FEV1), and the development of 
COPD.19 In this study, Schikowski and colleagues19 showed in a 
cross-sectional study of women, using the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) criteria to define 
COPD, that a 7 µg/m3 increase in ambient PM10 (over five 
years) was associated with a 5.1% more rapid decline in FEV1 
(Figure 1) and an odds ratio (OR) of 1.33 for the development 
of COPD. Moreover, they showed living less than 100 meters 
from a busy artery road had a significant (OR 1.79) detrimental 
effect on lung function.19 These findings suggest that long-term 
exposure to ambient PM10 and living near a major road both 
increase the risk of developing COPD and accelerate loss of 
lung function. It is interesting to note that in COPD, the PM, 
as opposed to gases such as nitrogen dioxide and ozone, are 
the strongest associated with increased mortality.37
Pathogenesis of PM-induced COPD
Clearance of PM from the lung
The main mechanisms of deposition of PM in the lungs 
are impaction, sedimentation, and diffusion.38 Impaction is 
thought to be the principal mechanism of large PM deposition 
(greater than 100 µm). Larger particles usually travel on an 
initial path until they are deflected by a branching airway. 
Sedimentation happens to particles that are allowed to fall 
under their own force of gravity. This mechanism is largely 
considered to affect those particles between the aerodynamic 
diameter of 0.1 µm and 50 µm. Finally, diffusion affects 
the smallest particles as they are displaced by random gas 
motion and will principally occur in the small airways and 
gas exchange regions of the lung.International Journal of COPD 2009:4 235
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The respiratory tract is lined with thin liquid layer known 
as the epithelial lining fluid (ELF). This fluid both covers 
and protects the epithelial cells and is composed of various 
neutralizing agents such as antioxidants, lysozyme defensins, 
lipids, mucins, and proteins.39 The main component of the 
ELF is surfactant, whose well documented main function is 
to reduce surface tension, but another ability of surfactant is 
to displace PM less than 6 µm in diameter to allow for easier 
mucociliary clearance.40 Proteins in surfactant, in addition 
to the possibility of opsonization, help macrophages target 
and clear PM.39 It seems, that in addition to the neutralizing 
agents and proteins natively present in surfactant, the ELF 
can lead to the physical aggregation of ultrafine PM into 
agglomerates of greater than 5 µm in diameter, which is 
more easily phagocytozed by macrophages.39 Some materials 
that land on the ELF are soluble, and these dissolve and may 
eventually transfer into the bloodstream.41 Another pathway 
for the soluble material to follow is the lymphatic channel, 
regional tracheobronchial lymph nodes, and eventually, to 
the blood circulation.38
Lung phagocytes are the first line of defense in the cellular 
response of the lungs to inhaled PM and microorganisms.42 
The most important of these lung phagocytes in PM clear-
ance is the alveolar macrophage (AM). AMs are located on 
the epithelial surfaces of either the alveoli or airways.43,44 
Particles that cannot be cleared by the mucociliary action and 
coughing are processed by macrophages.41,43 Their primary 
role is to act as a barrier to inhaled matter by phagocytosing 
particles and intracellularly processed them.41,45 For the most 
part, there is a direct, positive relationship between the extent 
of PM and the number of AMs.46 Several recent studies have 
pointed to ultrafine particles as more dangerous than larger 
particles47,48 supporting Brain’s46 observations in the 1960’s 
that per weight, smaller particles elicit a stronger inflamma-
tory response largely due to the greater number of particles 
and larger surface area to interact with biological surfaces.
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Figure 1 Association between FEv1 and long-term PM10 exposure (five-year mean). Data points are means of each place and year of study.
Abbreviations: FEv1, forced expiratory volume in one second; PM, particulate matter.International Journal of COPD 2009:4 236
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Alveolar macrophages can also go into an “overloaded” 
state,42 which inhibits their phagocytic and chemotactic activ-
ity when they have phagocytosed particles greater than 60% of 
their total internal volume.49,50 In a study by Morrow,50 it was 
found that if phagocytosed PM constituted only 6% of the total 
volume of AMs, the AMs ability to migrate to the mucocilliary 
escalator was compromised. Phagocytosis of certain particles 
such as silica, can damage or kill AM, releasing its contents that 
then fuels a perpetual inflammatory response.45 Furthermore, 
activation of AMs following PM phagocytosis, release copi-
ous amounts of oxygen radicals, proteases, pro-inflammatory 
mediators and growth-regulating proteins that can result in the 
pathogenesis of both acute and chronic lung inflammation.42,44
Lung inflammation induced by PM
Although much of the literature has focused on the size of the 
particles, numerous workers have explored the importance 
of the composition of PM.51 There is a plethora of sources 
for PM that are both geogenic and anthropogenic.52 The 
injurious effects of this ambient particulate matter (from 
either cigarette smoking or air pollution) are both local (in 
the lung) and systemic. The AMs and bronchial and alveolar 
epithelial cells are the principle cells that process inhaled 
airborne particles in the lung. In processing these particles, 
they produce pro-inflammatory mediators that have the abil-
ity to elicit both a local inflammatory response in the lung 
tissues, but also a systemic inflammatory response.53, 54
AM responses to PM exposure
Exposure of AM to atmospheric particles influences their 
phagocytic activity, increases their oxidant production, and 
releases pro-inflammatory mediators such as tumor necrosis 
factor (TNF)-α and interleukin (IL)-1ß that are important in 
mediating the local and systemic inflammatory response.54 
In addition to the acute response cytokines TNFα and IL-1β, 
AMs produce a broad range of other cytokines, in particular 
IL-6, IL-8, macrophage inflammatory protein (MIP)-1 and 
granulocyte macrophage colony-stimulating factor (GM-CSF) 
when incubated ex vivo to ambient particles.55 IL-8 is critically 
important as chemoattractant and leukocyte activator and facili-
tates the recruitment of both polymorphonuclear leukocytes 
(PMNs) and monocytes into the airspaces. GM-CSF is not 
only a hematopoietic growth factor but has also an important 
granulocyte degranulation factor that enhances tissue damage 
induced by granulocytes.56 IL-1β is one of the “acute response” 
cytokines that induces cytokine production by many cells 
and has a broad stimulating effect on B- and T-cells. IL-10, a 
cytokine known to inhibit the production of pro-inflammatory 
cytokines such as TNF-α, L-1β, IL-6 and IL-8, however, is not 
stimulated by particle exposure,55 suggesting that PM does not 
induce a significant anti-inflammatory cytokine response. Col-
lectively, these mediators released from AM when exposed to 
particles have the ability to elicit a pro-inflammatory response 
in the lung by stimulating other cells, such as, epithelial and 
endothelial cells that control and promote leukocyte recruitment 
into lung tissues and air spaces. In addition, exposure to ambi-
ent particles also compromise the response of AM to infectious 
agents possibly via an oxygen radical-mediated process by 
decreasing the AM’s ability to phagocytose bacteria.57–60 These 
studies suggested that the functional capacity of AM is modu-
lated by exposure to PM in such a manner that it decreases the 
lung host defences. Therefore, PM exposure and retention in 
the lungs of COPD subject are critically important in promot-
ing ongoing inflammation in the lung and could compromise 
local immune responses to infection resulting in more frequent 
COPD exacerbations.
Lung epithelial cell response to PM
Due to its large surface area, lung epithelial cells bear the brunt 
of exposure to inhaled particles and are critically important 
in processing these particles. Several studies,56,61–63 including 
studies from our own laboratory,61,62 have shown that lung epi-
thelial cells exposed to PM produce several pro-inflammatory 
mediators such as GM-CSF, IL-1β, IL-8, MCP-1, and leukemia 
inhibitory factor (LIF). These mediators are both important che-
moattractants for leukocytes and up-regulate the expression of 
adhesion molecules, such as inter-cellular adhesion molecule-1 
(ICAM-1), on their cell surface to promote leukocyte recruit-
ment into the airspaces. Furthermore, studies have implicated 
persistence of the E1A gene of adenovirus in the amplification 
of cigarette smoke-induced lung inflammation in subjects with 
COPD.64–67 Lung epithelial cells transfected with the E1A gene 
of adenovirus amplified the production of pro-inflammatory 
mediators following exposure to ambient particles,66,67 sug-
gesting additional pathways for how the retention of PM in 
the lung could contribute to persistence lung inflammation in 
COPD. Furthermore, studies from our laboratory have shown 
that exposure to ambient PM promote AM and lung epithelial 
interaction with synergetic production of pro-inflammatory 
mediators such as GM-CSF and IL-6.61 In human studies, it has 
also been shown that controlled exposure of volunteers to PM 
can induce an inflammatory response in the airways with an 
increase in neutrophil trafficking and inflammatory cytokines 
and chemokines in the airways.68,69 These inflammatory media-
tors can damage the airways, resulting a higher susceptibility to 
bacterial, fungal, or viral infections.63 These infections, in turn, International Journal of COPD 2009:4 237
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induce an adaptive immune response70 that can exacerbate the 
symptoms of asthma or COPD.
Collectively these studies suggest that AM and lung 
epithelial cells determine the profile and the magnitude of 
the mediator response in the lung following exposure to 
PM. Interestingly, these mediators are remarkably similar 
to mediators implicated in the pathogenesis, development, 
and progression of COPD, suggesting potential common 
inflammatory pathways stimulated when PM from different 
sources (cigarette smoke, ambient PM, wood smoke, etc.) 
are processed and retained in the lung.
Particulate matter in lung tissues of COPD
The major conduit for translocation of PM into the body is the 
respiratory tract.71 The majority of the biggest particles (5 µm) 
and the very smallest (0.001 µm) deposit in the nasal, pharyn-
geal, and laryngeal regions based on a predictive mathematical 
model from the International Commission on Radiological 
Protection in 1994.48,71 It is actually the particle range between 
0.1 and 0.001 µm that is clinically relevant because it is this 
fraction that is deposited in the alveolar ducts and sacs.71 The 
dose of inhaled particles delivered to any region of the lung 
depends on the balance between their deposition and clearance. 
There appears to be a tendency for particles to concentrate in 
the centrilobular emphysematous lesions.72 This association 
between PM accumulation and emphysematous destruction 
suggests that the retained particulates either drive the inflam-
matory process that underlies the pathogenesis of COPD, that 
these particles accumulate in regions of lung inflammation and 
cause destruction, or it could be a combination of these two 
processes. In previous studies from our laboratories, where we 
determined the relationship between severity of COPD and 
lung inflammation4 and observed the presence of retained PM 
in different lung tissues, in particular smaller airways, alveolar 
macrophages, bronchial associated lymphoid tissues (BALT), 
and blood vessels (Figure 2). Churg and colleagues73 showed 
accumulation of carbonaceous aggregates of ultrafine particles 
present in the small airway mucosa in four nonsmokers in 
highly polluted Mexico City, suggesting that PM penetrates 
into and is retained in the walls of small airways even in 
nonsmokers. They speculate that long-term exposure to high 
levels of ambient particulate pollutants results in small airway 
remodeling that could produce chronic airflow obstruction 
similar to what is observed in COPD.
Lung inflammation caused by PM in COPD
COPD is characterized by chronic airways inflammation and 
remodeling, lung parenchymal inflammation, and destruction 
resulting in expiratory airflow obstruction, hyperinflation of the 
lung with loss of elastic recoil and, ultimately, disturbance of 
gas exchange.5 The inflammatory process is characterized by 
the recruitment of inflammatory immune cells in the terminal 
conducting airways.4,5 This inflammatory response is also 
associated with a repair and remodeling process that obstructs 
the small conducting airways resulting in expiratory airflow 
limitation that is poorly reversible with the use of bronchodila-
tors.4,5,7,74,75 Increased numbers of neutrophils and macrophages 
are usually found in the small airways, with a mucosal increase 
in the numbers of inflammatory cells, including subepithelial 
CD68+ macrophages and CD8+ T-cells.4 Neutrophils are also 
increased in the bronchial walls and glands of patients with 
COPD further supporting a role of these cells in the patho-
genesis of airflow limitation.4,74,75 In an ex vivo model of PM 
exposure, Churg and colleagues76 used ambient PM and showed 
activation of nuclear factor-kappaB (NF-KB) in epithelial cells 
in rat tracheal explants. In their in vivo model, they showed that 
the inflammatory response in the small airways is character-
ized by tissue proliferation with thickening of airway walls and 
obstruction of airflow. It is reasonable to postulate that these 
changes in the smaller airways could contribute to the reten-
tion of PM in airways (Figure 2) and eventual progression of 
airways inflammation and obstruction.
In the lung parenchyma, inflammation in COPD is char-
acterized by accumulation of macrophages, neutrophils, and 
sometimes eosinophils in airspaces.4,5,7,74,75 This inflammatory 
reaction results in emphysematous destruction of alveolar 
walls thought to be induced by oxidative stress, apoptosis, 
and proteolysis of lung tissues.74,75,77,78 The nature of tissue 
inflammation favors tissue proliferation in the small airways 
and tissue destruction in the lung parenchyma.4,5 Clearly, 
distinct inflammatory pathways are activated in airway walls, 
in contrast to lung parenchyma that will influence the deposi-
tion and retention and possibly the inflammatory response 
elicited by PM in different regions of the lung.
Inflammatory mediators involved in COPD inflammation 
and those elicited by PM exposure of lung cells are remark-
ably similar. Increased levels of pro-inflammatory mediators 
such as IL-6, IL-1ß, TNF-α, and IL-8 have been observed 
in induced sputum from patients with stable COPD.79 These 
airway space mediators are produced predominantly by 
macrophages (IL-8, IL-1β, TNF-α, growth related onco-
gene-α [GRO-α], epithelial cell-derived neutrophil activat-
ing peptide [ENA-78], MCP-1, IL-10) and epithelial cells 
(IL-8, G-CSF, MCP-1) and are involved in neutrophil and 
monocyte recruitment into airspaces.80 Elastase and matrix 
metalloproteinase (MMP) activation that are released from 
neutrophils and macrophages are considered to be a important International Journal of COPD 2009:4 238
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mediators of lung parenchyma tissue damage in COPD, 
and recent studies showed that this process is driven by 
pro-inflammatory cytokines such as TNF-α which appears 
to be a key initiating mediator.81 Macrophage MMP activ-
ity and expression was upregulated in a study by Montano 
and colleagues,82 suggesting that this activity results in 
emphysematous destruction. Production of these mediators 
by PM deposited and retained in emphysematous regions of 
the lung will be able to activate the proteolytic pathway (eg, 
myeloperoxidase, elastase, MMP’s) and also stimulate the 
production of molecules such as IL-8 and ENA-78 involved 
in neutrophil recruitment and activation.
Figure 2 Particulate matter (PM) found in a) the blood vessel walls, b) lymphoid tissue, c) alveolar macrophages, d) Parenchyma, e) and airway wall, 
Sections from human lung tissuestained with H&E.International Journal of COPD 2009:4 239
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In a rat model, intratracheal instillation of PM10 
resulted in a neutrophil influx in combination with an 
increase in endothelial permeability.53 This study by Li and 
colleagues also showed that PM exposure precipitates free 
radical activity. PM has also been shown to be genotoxic to 
alveolar epithelial cells: causing both apoptosis and DNA 
damage through a mitochondria-related death and free 
radical pathway.83 This oxidative stress could be the result 
of structural damage inflicted onto the mitochondria by 
intracellular PM.84 In addition, PM also results in an induction 
of heme oxygenase-1 (HO-1), which is a key marker for oxi-
dative stress.84 Oxidative stress appears to be a very important 
pathway for the deleterious effects of PM exposure.85
Adverse health effects of PM  
in COPD
Exacerbations of COPD induced  
by PM exposure
Exacerbations are considered to be one of the most impor-
tant causes for morbidity and mortality linked with COPD.86 
COPD exacerbations are most likely caused by viral or 
bacterial infections. However, there are good epidemio-
logical data that implicate exposure to inhaled PM to either 
initiate or contribute with other factors such as infection, to 
precipitate exacerbations.3,86,87 Dominici and colleagues87 
reported a near doubling in admissions for COPD exacerbations 
for every 10 µgm3 of increase in PM2.5. Regardless of the dif-
ferent measures of PM exposure and health endpoints used in 
various studies; ultimately, they each support the association 
between PM exposure and increased COPD morbidity.3 In 
addition to morbidity, epidemiological evidence points to an 
increased mortality rate among COPD patients immediately fol-
lowing exposure to air pollution particles.3 Components of air 
pollution, such as, sulfur dioxide (SO2), nitrogen dioxide (NO2), 
and PM smaller than or equal to 10 um in aerodynamic diameter 
(PM10), have been all been implicated to increase respiratory 
mortality in COPD patients.88 For this reason, governments 
worldwide have introduced air quality guidelines. The goal 
of these guidelines are to decrease levels of deleterious PM;89 
however, levels are frequently exceeded. For example, in a 
study from the United Kingdom, levels exceeding guidelines 
have been implicated in 8,000 deaths and 10,000 excess hospital 
admissions annually from airway disease exacerbation.89
Development and progression of COPD 
induced by PM exposure
There is strong epidemiological evidence that exposure to ambi-
ent air pollutants causes exacerbations of pre-existing COPD, 
but very little evidence that it actually causes the development 
or progression of COPD. Schikowski and colleagues19 fol-
lowed women living near high traffic areas or industrial sources 
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Figure 3 Association between COPD and long-term PM10 exposure (five-year mean). Data points are means of each place and year of study.
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Table 1 Key studies in the role of particulate matter in the development and progression of COPD
Epidemiological evidence
Author(s) Study description
Schikowski et al19 Long term exposure to air pollution from high traffic and industrial sources resulted in 
rapid decline of FEv1, a high risk ratio to develop COPD, and poorer respiratory health
Liu et al18 Significant association between prevalence of COPD and biomass fuel for cooking in 
rural China
viegi et al21 Exposure to PM by internal combustion and industrial emissions recognized as significant 
contributors to exacerbation of COPD
Dockery et al32 relationship between increased levels of air pollution and mortality and morbidity rates 
from respiratory diseases
Torres-Duque et al23 Indoor air pollution from the combustion of biomass fuels related to respiratory diseases
Sunyer et al1 Effect of acute increase in urban air pollution on respiratory health and what factors 
could attribute to this effects
Sint et al3 COPD patients have an increased sensitivity to PM and should reduce their exposure to 
PM whenever possible
Alveolar macrophage (AM) response to PM
van Eeden et al54 Exposure of lung macrophages to atmospheric particles influences their phagocytic 
activity and pro-inflammatory responses
Oberdorster et al71 Suggests a duel role of lung macrophages exposed to PM: both preventing and contribut-
ing to chronic lung injury
Morrow50 reviews possible mechanisms as to how dust overloading can compromise the phago-
cytic and chemotactic ability of AMs
Lung inflammation in response to PM
Churg et al76 Particulate matter activates NF-KB in tracheal epithelial cells
Montano et al82 Increase MMP activity in macrophages exposed to wood smoke, suggesting subsequent 
emphysematous destruction
risom et al85 Particulate matter induced oxidative stress-induced DNA damage is an important ways in 
which PM can be harmful
Li et al53 PM induces HO-1, key marker for oxidative stress resulting in structural damage of 
mitochondria
Abbreviations: COPD, chronic obstructive pulmonary disease; FEv1, forced expiratory volume in one second; PM, particulate matter.
longitudinally, and showed that long term exposure to air 
pollution from these sources resulted in more rapid decline in 
pulmonary function (FEV1), a high risk ratio to develop COPD, 
and have poorer respiratory health (Figures 1 and 3). This study 
was the first to assess the impact of long-term air pollution 
on the development of COPD. In a cross-sectional study, Liu 
and colleagues18 showed a significant association between the 
prevalence of COPD and exposure to biomass fuel for cook-
ing in rural China (corrected for multiple factors including 
smoking). This finding is supported by study from Kiraz and 
colleagues90 showing that rural Chinese women exposed to 
biomass fumes are more likely to suffer from chronic bronchitis 
and COPD than urban women even though the prevalence of 
smoking is higher among the latter group. The World Health 
Organization (WHO) has estimated that more than 1.6 million 
deaths and over 38.5 million disability-adjusted life-years can 
be attributable to indoor smoke from the use of biomass fuels, 
affecting mainly children and women.23 Together these studies 
suggest that exposures other that tobacco smoke could also 
lead to the development of COPD. Interestingly, a wide range 
of studies suggest that only 15% to 25% of smokers actually 
develop clinical COPD, but virtually 100% of smokers have 
airway inflammation that may include observable respiratory 
bronchiolitis.89,91 These observations underline the importance 
of the interaction of genetic factors and susceptibility with 
environmental exposures to produce clinical COPD. Sezer and 
colleagues92 found in a case control study that women afflicted 
with COPD, that exposure to both cigarette and biomass smoke 
for 30 or more years, were significant risk factors in the devel-
opment of COPD. Earlier studies by Fletcher and Peto93 have 
shown that loss in lung function in smokers that develop COPD 
is a progressive process even after smoking cessation. This con-
cept was supported by Hogg and colleagues:78 they showed an 
intense inflammatory response in the lungs of patients with end International Journal of COPD 2009:4 241
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stage COPD who have stopped smoking for prolonged period of 
time. It is reasonable to postulate that risk factors independent 
of cigarette smoking such as occupational and environmental 
exposures cause progression of the disease process.
Conclusions
COPD is a chronic inflammatory condition of the airways 
and lung parenchyma and the importance of exposure and 
retention of particulate matter in the lung tissues on the 
pathogenesis of lung inflammation in COPD is still unclear. 
Numerous epidemiological studies have implicated exposure 
to a variety of ambient particles and gases to exacerbate 
symptoms of COPD, resulting in an increase in morbidity 
and mortality (Table 1). The predominant source of PM in the 
lungs of COPD patients is either PM inhaled from cigarette 
smoke or ambient air pollution particles from other sources: 
both have been associated with the development and progres-
sion of COPD. With the rapid urbanization of the population, 
a better understanding of the importance of the different 
sources of ambient PM on the development and progression 
of COPD is imperative for educational and preventative mea-
sures. Furthermore, determining the importance of retained 
PM in perpetual lung inflammation in COPD could lead to 
novel therapeutic interventions in the future.
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